Efficacy and Safety of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis With and Without Food Allergies
Michael S. Blaiss(Augusta University), Jonathan M. Spergel(University of Pennsylvania), Chuanbo Zang(Pfizer (United States)), Liza Takiya(Pfizer (United States)), Aharon Kessel(Technion – Israel Institute of Technology), John L. Werth(Pfizer (United States)), Michael J. Cork(Royal Hallamshire Hospital), Michael O’Connell(Pfizer (United States)), Peter Lio(Northwestern University)
Cited by 0
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k